-
Analysts anticipate lower sales of blockbuster cancer drug Revlimid to squeeze Dr Reddy's margins for Q3, thereby dragging earnings growth.
-
Net Sales are expected to increase by 22.3 percent Y-o-Y (down 3.1 percent Q-o-Q) to Rs 6,099.1 crore, according to Nirmal Bang.
-
Revlimid sale contribution to US revenue likely to fall as it normalises, making for a muted December Quarter
-
Dr Reddy’s North American operations will set the tone for the September quarter performance, as likely price erosion will trigger a decline in sales on a year-on-year basis
-
During the current quarter, Dr Reddy’s stands to gain from the receipt of $72 million from the settlement of the Suboxone dispute with Indivior.
-
Net Sales are expected to increase by 7.7 percent Y-o-Y (down 2.7 percent Q-o-Q) to Rs 5,324.7 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 9,7 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs 5,394.2 crore, according to Prabhudas Lilladher.
-
ICICI Securities expects the India business to grow 10 percent YoY and that in the US by 12.8 percent QoQ led by new launches. It also foresees Russia, CIS & ROW (Rest of World) to show steady growth
-
Net Sales are expected to increase by 4.9 percent Y-o-Y (up 4.2 percent Q-o-Q) to Rs 5,153.4 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 19.1 percent Y-o-Y (up 10.5 percent Q-o-Q) to Rs 5,270.1 crore, according to KRChoksey.
-
Net Sales are expected to increase by 10.9 percent Y-o-Y (up 3 percent Q-o-Q) to Rs 4,910.8 crore, according to ICICI Direct.
-
The company is expected to report double-digit growth in revenue on the back of the Wockhardt acquisition and good business in India and Europe but a drop in the US sales may dent profitability.
-
Net Sales are expected to increase by 9 percent Y-o-Y (down 1.9 percent Q-o-Q) to Rs. 4,849.3 crore, according to Sharekhan.
-
Brokerage firm Kotak Institutional Equities expects the company's US business to increase by $8 mn quarter-on-quarter (QoQ) to $255 mn, led by the launch of Kuvan.
-
Net Sales are expected to increase by 16.5 percent Y-o-Y (up 4.3 percent Q-o-Q) to Rs. 5,121.8 crore, according to Yash Securities.
-
Net Sales are expected to increase by 12.3 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 4,397.1 crore, according to Prabhudas Lilladher.
-
Sharekhan sees 167 bps increase in EBITDA margin due to cost savings and better revenue performance.
-
The company has filed 20 formulations across the global markets, with three Abbreviated New Drug Application (ANDAs) in the US. It has filed 20 Drug Master Files (DMFs) across the markets, with three DMFs in the US.
-
HSBC also maintained buy call on the stock and raised price target to Rs 3,430 (from Rs 3,230 earlier)
-
Net Sales are expected to increase by 9.7 percent Y-o-Y (up 8.4 percent Q-o-Q) to Rs. 4,167.1 crore, according to Emkay.
-
Net Sales are expected to increase by 2.2 percent Y-o-Y (down 5.2 percent Q-o-Q) to Rs. 3,820.3 crore, according to Prabhudas Lilladher.
-
Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter
-
Net Sales are expected to increase by 7.7 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 3,807.5 crore, according to Kotak.
-
Net Sales are expected to increase by 12.4 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs. 3,994.3 crore, according to Prabhudas Lilladher.
-
While maintaining buy call with a price target at Rs 2,704, Japanese brokerage firm Nomura said company's operating performance was ahead of its expectations.
